Merck & Co. and Moderna maintain a decade-long collaboration centered on their personalized mRNA cancer vaccine intismeran autogene combined with Keytruda, which delivered statistically significant Phase 3 success in resected melanoma in August 2026, driving sharp share-price gains for both. This alliance already delivers substantial commercial and R&D synergies without requiring a full merger or acquisition, consistent with the 98.8% market-implied probability against such a deal being announced in 2026. Traders price in continued independent operations amid Keytruda’s patent cliff and Moderna’s post-COVID revenue shift. Tail risks remain low but include unforeseen regulatory setbacks or strategic pivots if either firm encounters acute capital needs or competitive threats that alter board-level incentives.
Ringkasan eksperimental yang dihasilkan AI dengan referensi data Polymarket. Ini bukan saran trading dan tidak berperan dalam bagaimana pasar ini diselesaikan. · Diperbarui1% peluang
BARU
BARU
Dec 31, 2026
1% peluang
BARU
BARU
Dec 31, 2026
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Merck & Co. and Moderna maintain a decade-long collaboration centered on their personalized mRNA cancer vaccine intismeran autogene combined with Keytruda, which delivered statistically significant Phase 3 success in resected melanoma in August 2026, driving sharp share-price gains for both. This alliance already delivers substantial commercial and R&D synergies without requiring a full merger or acquisition, consistent with the 98.8% market-implied probability against such a deal being announced in 2026. Traders price in continued independent operations amid Keytruda’s patent cliff and Moderna’s post-COVID revenue shift. Tail risks remain low but include unforeseen regulatory setbacks or strategic pivots if either firm encounters acute capital needs or competitive threats that alter board-level incentives.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
Pasar Dibuka: Aug 19, 2026, 3:58 PM ET
Volume
$430Tanggal Berakhir
Jan 1, 2027Pasar Dibuka
Aug 19, 2026, 3:58 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Merck & Co. and Moderna maintain a decade-long collaboration centered on their personalized mRNA cancer vaccine intismeran autogene combined with Keytruda, which delivered statistically significant Phase 3 success in resected melanoma in August 2026, driving sharp share-price gains for both. This alliance already delivers substantial commercial and R&D synergies without requiring a full merger or acquisition, consistent with the 98.8% market-implied probability against such a deal being announced in 2026. Traders price in continued independent operations amid Keytruda’s patent cliff and Moderna’s post-COVID revenue shift. Tail risks remain low but include unforeseen regulatory setbacks or strategic pivots if either firm encounters acute capital needs or competitive threats that alter board-level incentives.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
Volume
$430Tanggal Berakhir
Jan 1, 2027Pasar Dibuka
Aug 19, 2026, 3:58 PM ETResolver
0x65070BE91...Merck & Co. and Moderna maintain a decade-long collaboration centered on their personalized mRNA cancer vaccine intismeran autogene combined with Keytruda, which delivered statistically significant Phase 3 success in resected melanoma in August 2026, driving sharp share-price gains for both. This alliance already delivers substantial commercial and R&D synergies without requiring a full merger or acquisition, consistent with the 98.8% market-implied probability against such a deal being announced in 2026. Traders price in continued independent operations amid Keytruda’s patent cliff and Moderna’s post-COVID revenue shift. Tail risks remain low but include unforeseen regulatory setbacks or strategic pivots if either firm encounters acute capital needs or competitive threats that alter board-level incentives.
Ringkasan eksperimental yang dihasilkan AI dengan referensi data Polymarket. Ini bukan saran trading dan tidak berperan dalam bagaimana pasar ini diselesaikan. · Diperbarui
Hati-hati dengan link eksternal.
Hati-hati dengan link eksternal.
Pertanyaan yang Sering Diajukan